19:24 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

AGTR1 inhibitor nanoconjugate boosts chemo, immunotherapies in cancers

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer; breast cancer Mouse studies suggest a nanoconjugate based on the generic ATGR1 inhibitor valsartan could enhanced the efficacy of chemotherapies and checkpoint inhibitors in pancreatic and metastatic breast cancers....
21:12 , Feb 22, 2018 |  BC Innovations  |  Finance

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
07:00 , Jul 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Angiotensin II type 1 receptor (AGTR1)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest AGTR1 inhibitors could help sensitize obese pancreatic ductal adenocarcinoma (PDAC) patients to chemotherapy. In PDAC patients who underwent surgical tumor resection, adjuvant chemotherapy increased survival...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

Simcere, Merck deal

The partners amended a 2011 JV under which the companies were commercializing a combined portfolio of off-patent cardiovascular and metabolic drugs. In a joint statement, the companies said “in order to pursue further development and...
02:08 , Feb 7, 2015 |  BC Extra  |  Top Story

Merck, Simcere JV fallout

A high-profile China joint venture formed in 2011 between Simcere Pharmaceutical Group (Nanjing, China) and Merck & Co. Inc. (NYSE:MRK) appears to be coming to an end, with Simcere taking over management of SMSD (Shanghai)...
07:00 , Apr 3, 2014 |  BC Innovations  |  Targets & Mechanisms

Narrowing down graft stenosis

One of the dominant problems after coronary artery bypass graft surgery is hyperplastic growth inside the transplanted blood vessel that can lead to stenosis. Now, a team at the NIH 's National Heart, Lung, and...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Clinical News

Losartan: Phase III discontinued

Researchers at the VA and colleagues said the double-blind, U.S. Phase III VA NEPHRON-D trial in 1,448 Type II diabetics with overt nephropathy was stopped early after once-daily 100 mg losartan plus once-daily lisinopril -...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

Patiromer: Additional Phase IIb data

Relypsa reported additional data from the open-label, international Phase IIb AMETHYST-DN trial in 306 patients with hyperkalemia due to Type II diabetes and CKD who received oral patiromer plus renin-angiotensin-aldosterone system (RAAS) inhibitor therapy for...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Clinical News

Cozaar losartan cardiovascular data

The investigator-sponsored, Dutch COMPARE trial in 233 adults with Marfan syndrome showed that Cozaar significantly reduced aortic root enlargement as measured by MRI at 3 years vs. untreated controls (0.77 vs. 1.35 mm, p=0.014). Additionally,...
07:00 , May 13, 2013 |  BioCentury  |  Product Development

An association for dissociation

Forest Laboratories Inc. 's investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development...